- Home
- EBMT vs TLSA Comparison
EBMT vs TLSA Comparison
Compare EBMT & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | TLSA |
|---|---|---|
| Founded | 1922 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 164.1M |
| IPO Year | 2009 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EBMT | TLSA |
|---|---|---|
| Price | $21.61 | $1.39 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | 39.9K | ★ 243.8K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 53.23 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $43.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.11 | $1.14 |
| 52 Week High | $23.95 | $2.60 |
Technical Indicators
Market Signals| Indicator | EBMT | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 47.02 |
| Support Level | $21.59 | $1.24 |
| Resistance Level | $22.72 | $1.54 |
| Average True Range (ATR) | 0.51 | 0.15 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 1.56 | 14.55 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.